UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society’s Virtual Event AES2020

ATLANTA, Dec. 4, 2020 /PRNewswire/ — UCB today announced that 15 scientific posters will be presented at the upcoming American Epilepsy Society’s all new virtual event, AES2020, December 4-8, 2020. The scientific program features the latest research on VIMPAT in primary generalized tonic-clonic seizures (PGTCS). VIMPAT was just recently approved by the U.S. Food and Drug Administration (FDA) as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.1

Key poster presentations also include data on the long-term efficacy and tolerability of adjunctive BRIVIACT in adults with partial-onset seizures, the efficacy and patient satisfaction of NAYZILAM among people living with seizure clusters, and Phase 2 study results for Staccato® Alprazolam, an investigational drug-device combination designed to be used as a single-use epileptic seizure rescue therapy that combines the Staccato® delivery technology with alprazolam. Staccato® Alprazolam is not yet approved by the FDA.

Read More